Albumedix Ltd

Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. We partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with more than 80 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.

Dr Phil Morton
Chief Technology Officer 
Jonas Skjødt Møller
Chief Operating Officer 
Dr Joanna Hay
Account Director, Europe 

National Institute for Health Research (NIHR) Clinical Research Network

Exhibiting at booth 5b

Working in partnership with the life sciences industry

  • Access to NHS clinical expertise
  • Accurate national and local feasibility
  • Streamlined site identification
  • Study set-up support 
  • Proactive performance monitoring  
  • All free of charge

Funded by the UK government, the National Institute for Health Research (NIHR) Clinical Research Network (CRN) delivers high quality research in partnership with the UK’s National Health Service (NHS). Our Study Support Service is free of charge and helps the life sciences industry plan, set-up and deliver high quality research to time and target, across all therapeutic areas. 

We are your route to accessing the UK’s unified research system - the most integrated health research system in the world.

Natalie Wilson
Business Development Manager 
Theo Christie
Business Development Manager 
Sinead Collinge
Operations and Business Development Manager 

Neem Biotech

Neem Biotech is an R&D pharmaceutical biotech with expertise in novel antimicrobial research and drug development based on bacterial quorum sensing inhibition pathways.

Neem is a virtual SME with a footprint in South Wales. It has in-house chemistry and biology expertise and a leadership team with extensive antibacterial drug development experience. Neem is also linked in to a network of clinical and disease-area experts in wound and respiratory indications.

Dr Graham Dixon
CEO Neem Biotech 
Heather Graz
Commercial Development Manager Neem Biotech 

SYNthesis Research

SYNthesis Research is a research “venture partner” that draws upon a deep well of experience in small molecule drug discovery, to partner with the outstanding biology of our collaborators to develop and mature new drug candidates for a broad range of therapeutic applications.

As well as developing our own pipeline of early-stage projects, SYNthesis Research has developed partnerships with the Walter and Eliza Hall Institute for Medical Research, and the Cancer Therapeutics Co-operative Research Centre (CTx-CRC), inter alia.

SYNthesis Research brings management, expertise and financing to the table, and our sister company, SYNthesis med chem, brings a chemistry-focussed contract research service to our collaborations, providing custom synthesis, medicinal chemistry and fully integrated drug discovery capabilities that delivers cost effective high quality drug discovery and development capability.

We are seeking innovation partners for shared risk, in-licensing and partnering.

Simon Bury
Global Head of Business Development 
Prof Andrew Wilks